Volociximab

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search
Volociximab
Monoclonal antibody
TypeWhole antibody
SourceChimeric (mouse/human)
Targetα5β1 integrin
Clinical data
ATC code
  • none
Identifiers
CAS Number
ChemSpider
  • none
UNII
KEGG
Chemical and physical data
FormulaC6434H9942N1706O2040S52
Molar mass145.5 kg/mol g·mol−1
 ☒N☑Y (what is this?)  (verify)

Volociximab (also known as M200) is a chimeric monoclonal antibody jointly developed by PDL BioPharma and Biogen Idec for treatment of a variety of advanced solid tumors. It binds to and inhibits the functional activity of α5β1 integrin.[1]

It is thought to reduce metastases. Early results show potential in renal cell cancers.[citation needed]

References[edit]

  1. ^ Ng, CM; Bai, S; Takimoto, CH; Tang, MT; Tolcher, AW (2009). "Mechanism-based receptor-binding model to describe the pharmacokinetic and pharmacodynamic of an anti-alpha(5)beta (1) integrin monoclonal antibody (volociximab) in cancer patients". Cancer chemotherapy and pharmacology. 65 (2): 207–17. doi:10.1007/s00280-009-1023-8. PMID 19468731.

External links[edit]